(Q46407742)

21 December 2017

title

VALIANT (VALsartan In Acute myocardial iNfarcTion) trial (English)

1 reference

21 December 2017

acute myocardial infarction

main subject

1 reference

1

1 reference

21 December 2017

author name string

Gianna Fabbri

series ordinal

2

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

21 December 2017

Expert Opinion on Pharmacotherapy

published in

1 reference

21 December 2017

volume

6

1 reference

21 December 2017

issue

3

1 reference

21 December 2017

page(s)

507-512

1 reference

21 December 2017

Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.507

21 January 2018

Identifiers

DOI

10.1517/14656566.6.3.507

1 reference

21 December 2017

1 reference

21 December 2017